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ABSTRACT* 
Objective: To compare the prescribing practice and 
pharmacotherapy outpatient cost of hypertension 
and its common complications between two 
neighboring countries, Bulgaria and Serbia. The 
study questions focus on consistency of the 
prescribing practice with the treatment guidelines; 
comparability of the treatment patterns among both 
countries, and burden of hypertension cost to the 
population and third party payer in the countries 
under consideration. 
Methods: Retrospective study, one year time 
horizon is for outpatient therapy. 
Results: Patients with arterial hypertension in 
Bulgaria are most often on monotherapy (61% vs 
6% in Serbia), as well as those with complications 
(66% vs 0% Serbia). In both countries the first 
choice of therapy are the ACE inhibitors (37.01% in 
Serbia and 41% in Bulgaria) and then follows the 
calcium antagonists, beta-blockers, and diuretics. 
The weighed monthly cost of hypertension and 
complicated hypertension is almost doubled in 
Serbia (12.56 vs 8.23 EUR for hypertension, and 
13.39 vs 8.23 EUR) and prevailing part is 
reimbursed (88% vs 44% in Bulgaria). 
Conclusion: Our study confirms that hypertension 
and its complications therapy consumes a huge 
amount of financial resources. In both countries 
under consideration the therapy is corresponding 
with the European treatment guidelines. The 
international cost comparisons are possible but they 
depend on many external factors as the regulatory 
measures, prescribing habits and reimbursement 
policy and should be analysed within this 
framework. 
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COSTE DE LA FARMACOTERAPIA 
ANTIHIPERTENSIVA AMBULATORIA: 
ESTUDIO COMPARATIVO ENTRE 
BULGARIA Y SERBIA 
 
RESUMEN 
Objetivo: Comparar las prácticas de prescripción y 
el coste del tratamiento ambulatorio de la 
hipertensión y sus complicaciones comunes en dos 
países vecinos, Bulgaria y Serbia. Las preguntas de 
investigación se centran en la consistencia de las 
prácticas de prescripción con las guías de 
tratamiento; la comparabilidad de los patrones de 
prescripción entre los dos países, y el peso del coste 
de la hipertensión para la población y las 
aseguradoras en los países en estudio. 
Métodos: Estudio retrospectivo con un horizonte 
temporal de un año para el tratamiento ambulatorio. 
Resultados: Los pacientes con hipertensión arterial 
en Bulgaria están más frecuentemente en 
monoterapia (61% vs 6% en Serbia). En ambos 
países la primera elección de tratamiento son los 
IECA (37,01% en Serbia y 41% en Bulgaria) 
seguidos de los calcio-antagonistas, 
betabloqueantes y diuréticos. El coste mensual 
ponderado de la hipertensión complicada es casi el 
doble en Serbia (12,56 vs 8,23 EUR para 
hipertensión y 13,39 vs 8,23 EUR) y la parte 
principal es reembolsada (88% vs 44% en 
Bulgaria). 
Conclusión: Nuestro estudio confirma que la 
hipertensión y sus complicaciones consumen una 
enorme cantidad de recursos financieros. En ambos 
países estudiados el tratamiento se corresponde con 
las guías europeas de tratamiento. Las 
comparaciones internacionales de costes son 
factibles pero dependen de muchos factores 
externos como las medidas regulatorias, los hábitos 
de prescripción y las políticas de reembolso, y 
deberían analizarse en estos marcos. 
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INTRODUCTION 
Arterial hypertension is one of the leading risk 
factors for ischemic heart disease, cerebrovascular 
diseases, peripheral arterial diseases, stroke and 
acute myocardial infarction that are among the most 
health care cost consuming diseases. 
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Cardiovascular diseases were the leading cause of 
mortality in Serbia in 2006, with 57.6% of all deaths, 
and women (53.9%) died more often than men.1 
Age-standardized mortality rate for cardiovascular 
diseases is 554.0 per 100,000 Bulgarian population2 
and hypertension is also among the leading causes 
for death (108.1 per 100,000).3 Hypertension 
complication leads to age-standardized annual 
event rate from 915 to 30 per 100,000 people all 
over the world.4,5 Premature death and disability 
due to cardiovascular diseases represent significant 
economic and social burden to any country, which is 
recognized by European Society of Hypertension.6 
Studying the hypertension prescribing practice is 
important not only from the therapeutic point of view 
but also from the economic point, especially when it 
is connected with the cost of the complications.  
The aim of this study is to compare the prescribing 
practice and pharmacotherapy outpatient cost of 
hypertension and its common complications 
between two neighbouring countries Bulgaria and 
Serbia.  
Study questions:  
- Is the hypertension prescribing practice in both 
countries consistent with the treatment 
guidelines? 
- Are the treatment patterns comparable among 
both countries?  
- What is the burden of hypertension cost to the 
population and third party payer in the countries 
under consideration?  
The studies are the retrospective ones, the point of 
view is that of the outpatient therapy and time 
horizon is for one year. 
In Serbia the total number of patient with 
hypertension, codes I10-I11 was 2764 while in 
Bulgaria the whole sample is including 3240 
patients. Patients without complications of 
hypertension were 1856 in Serbia and 2106 in 
Bulgaria that represent 67.15% and 65% 
respectively. Patients with complicated hypertension 
were 908, or 32.85% in Serbia and 1134 (35%) in 
Bulgaria. 
 
METHODS  
The studies in the two countries were organized 
consecutively and independently following the same 
methodological approach and then the results were 
compared. 
A one year retrospective study from the point of 
view of health care systems in Bulgaria and Serbia 
was performed in 2006. 
A prescription sample size was determined to 
satisfy the values for alpha 0.05 and a study power 
of 0.80. The size of 250 prescriptions per diagnosis 
satisfies the stated criteria.  
Prescribing practice analysis 
In Bulgaria on a retrospective random basis were 
collected 3240 reimbursable prescriptions in 2006 
year from the pharmacies databases working under 
National health insurance fund (NHIF) conditions. In 
Serbia the information database of the Republic 
Institute of Health Insurance (RIHI) was used as a 
source of the analysis. The list of all insured 
persons according, that betake medications on 12 
or more prescriptions per year (depict on chronic 
disease and regular therapy) was created and out of 
this list the random sample of patients was collected 
for the following conditions defined by the 
International classification of diseases (ICD)7: 
hypertension (I10-I11) and for its complications - 
heart failure (І.50); sequelae of cerebrovascular 
disease (І.69); angina pectoris (І.20). In Bulgaria 
according to NHIF rules 1 patient can receive only 1 
prescription for one health condition per month 
including no more than 3 medicines while in Serbia 
there is no such a limitation.  
The medicines in the collected samples were 
systematized and analyzed according to the 
following criteria: 
- complexity of the therapy – mono-, di-, three-, 
etc.); 
- frequency of the prescribed medicines as 
therapeutic class; international nonproprietary 
names; and brand name. 
Prescription cost calculation 
In the prescribing cost calculation were considered 
the following outcome indicators.  
- total number of patients (n) by ICD diagnosis of 
arterial hypertension or with complicated 
hypertension;  
- number of patients with ICD codes I10-I11(n) 
that except the I10-I11 possess and one or more 
of hypertension complications: angina pectoris 
(I20), myocardial infarct (I21), ischemic hard 
disease (I25), cardiac insufficiency (I50), insult 
(I69); In Bulgaria only angina pectoris, cardiac 
insufficiency and insult were considered for the 
analysis.  
- frequency of patients (p) with hypertension out 
of all collected patients and frequency of 
patients with complications (p) complicated 
hypertension out of all patients with 
hypertension;  
- number of patients (n) on mono-, di-, three- or 
poly therapy out of all patients with hypertension 
and out of all patients with complicated 
hypertension;  
- frequency of monthly prescribing of trade names 
of medicines (p) in the groups of patients on 
mono-, di-, three- and poly therapy for 
hypertension and complicated hypertension, 
calculated as a number of dispensed packages 
of medicines per patient on mono- ; di-; three- 
etc- therapy;  
- weighed monthly cost of pharmacotherapy (Σ) 
per patient on mono-, di-, three- and poly-
therapy for hypertension and simple 
hypertension, calculated using the following 
formula:
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where:  
Σ1, 2 …i is in Bulgaria the officially published retail 
price negotiated with NHIF8 while in Serbia is an 
average monthly price of package of prescribed 
dosage form9; 
p1, 2 …i is a frequency of monthly prescribing of the 
same trade name. 
There are a variety of the co-payment in the 
reimbursement drug list in Bulgaria for the 
medicines for hypertension therapy and its 
complications that impose a separated calculation 
for the reimbursed part of the cost and co-payment 
contribution.8 The same was also completed for the 
complicated hypertension. 
The total cost of yearly therapy is calculated as a 
sum of the cost of all hypertension patients for 12 
months (AHU), calculated as 12 monthly therapy 
costs multiplied by the number of patients with 
hypertension: 
 
Statistical analysis 
Differences in proportions between the prescribing 
practice and cost of hypertension and complicated 
hypertension therapy in Bulgaria and Serbia were 
compared with the two-sided z-test for two 
proportions. We estimated 95% confidence intervals 
(CI) assuming a normal distribution. The z value 
and 95% confidence interval z value were analyzed 
using Excel.  
 
RESULTS  
In Serbia the total number of patient with 
hypertension, codes I10-I11 was 2764 while in 
Bulgaria the whole sample is including 3240 
patients. Patients without complications of 
hypertension were 1856 in Serbia and 2106 in 
Bulgaria that represent 67.15% and 65% 
respectively. Patients with complicated hypertension 
were 908, or 32.85% in Serbia and 1134 (35%) in 
Bulgaria.  
 
Table 1. 
 Serbia Bulgaria Z value  
 
indicator N % N %    
Total sample 2764   3240     
Prescriptions for AH  1856 67.15 2106 65 1.602 
Monotherapy 118 06.36 1296 61.54 36.13* 
Ditherapy 552 29.74 647 30.72 0.647 
Three therapy                   653 35.18 162 7.69 20.912* 
Polytherapy 533 28.72 0 0 5.347* 
Prescriptions for complicated AH(CAH) 908 32.85 1134 35 1.602 
Monotherapy 0 0 745 65.70 9.474* 
Ditherapy 90 9.91 285 25.13 8.642* 
Three therapy                   255 28.08 104 9.17 11.187* 
Polytherapy 563 62.00 0 0 9.133* 
AH therapy by pharmacological groups           
ACE inhibitors   37.01   41 0.435 
ACE inhibitors with diuretics   2.67   0 0.505 
calcium antagonist   21.6   16 0.901 
beta blockers   12.88   19 0.964 
diuretics   10.03   15 0.855 
other    15.81   9 0.461 
Expenditures €  value   value     
waged monthly cost for AH (Euro) 12.56   6.9    
waged monthly cost of hypertension considering 
the chance of having complications (Euro) CAH 
13.39   8.23    
RIHI participation of total expenditures in 
monthly therapy of AH per patient 
10.70 88.44 3.04 44.06 6.419* 
RIHI participation of total expenditures in 
monthly therapy of CAH per patient 
13.36 83.45 3.96 36.77 6.628* 
Distribution of complications from CAH          
angina pectoris   70   42 3.846* 
heart failure   7   26 3.429* 
ischemic heart disease   6   0 1.539 
sequelae of cerebrovascular disease    0. 33   32 5.715* 
other diagnoses in combination with AH   16.67   0 3.706* 
*p < 0.05 
AH, arterial hypertension; CAH, complicated arterial hypertension; ACE, Angiotensin-Converting Enzyme; RIHI, 
Republic Institute of Health Insurance 
 
Distribution of patients according to available 
complications is following. Angina pectoris is 
leading complication with 70% in Serbian sample 
and 42% in Bulgarian, then follows heart 
insufficiency (7% and 26%), ischemic heart disease 
(6% for Serbia no information for Bulgaria), 
sequelae of cerebrovascular disease (0.33% and 
0.32 %), and other diagnoses 16.7% in Serbia. In 
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complicated hypertension prevails the mono-
therapy in Bulgaria for 66%, while in Serbia 62% of 
patients are using more than three medicines (Table 
1).  
Patients with hypertension in Bulgaria are most 
often on mono-therapy (61% vs 6% in Serbia), as 
well as those with complications (66% vs 0% 
Serbia). The mono-therapy in hypertension 
treatment prevails in Bulgaria in 1296 patients while 
in Serbia only 118 patients are on mono therapy. 
Two medicines were prescribed in 30% and 29% 
respectively, while the three therapies prevail in 
Serbia with 35%. More than three medicines have 
been prescribed in 28% of the observed patient 
sample in Serbia.  
In spite of the differences in the complexity of the 
therapy it was not observed statistically significant 
differences among the prescribed therapeutic 
classes of medicines (Table 1). In both countries the 
first choice of therapy are the ACE inhibitors 
(37.01% in Serbia and 41% in Bulgaria) and then 
follows the calcium antagonists, beta-blockers, and 
diuretics. 
The weighed monthly cost of hypertension and 
complicated hypertension is almost doubled in 
Serbia (12.56 vs 8.23 Euro for hypertension, and 
13.39 vs 8.23 Euro) and prevailing part is 
reimbursed (88% vs 44% in Bulgaria). 
 
DISCUSSION 
There are some estimation that the total number of 
patients with hypertension in Serbia is around 1 400 
000, which correspond to 17.97% prevalence (7.4 
million population).10 For Bulgaria the corresponding 
figure is 1.5 million hypertensive patients (7.2 million 
inhabitants).11 The number of patients with 
hypertension and complicated hypertension is 
similar in both country samples and this similarity is 
statistically significant (Table 1). The structure of the 
patients with complications differs because in 
Bulgaria only the 3 main complications were 
included in the sample, while in Serbia was 
considered also and other complications. The fact 
that there were no patients on poly therapy in 
Bulgaria could be explained with the health 
insurance fund limits to prescribe no more that 3 
medicines per prescription, per diagnosis per month 
for a particular patient. This rule affects all the 
prescribing structure. The fact that patients in 
Bulgaria are most often on mono-therapy could be 
explained with the same regulation because 
patients receive a medicines for particular 
diagnoses and for the main disease as is the 
hypertension on the same prescription. We 
recognize that the marginal use of combination 
therapy in Bulgaria contrasts with the 2007 
ESH/ESC guideline’s recommendations for 
hypertension therapy. There was a thorough debate 
among the health practitioners and NHIF in Bulgaria 
about the possible negative impact that this 
limitation could have on a proper handling with the 
high blood pressure and now a day are going 
changes in the positive drug list. There were 
included a combination products within it. We could 
not comment the final results because the process 
of medicines selections is still in process but we 
believe that it will be beneficial for the patients. In 
Serbia patients receive prescriptions for all 
diagnoses together.  
The fact that there is a similar structure of the 
prescribing by the main therapeutic classless 
means that professionals’ in both countries follows 
the contemporary treatment guidelines. Further 
researches are necessary not only on cost control 
measures but also there on the need of physician 
education on rational drug therapy, and risk 
screening among the population. The fact that there 
are patients using more than 4 medicines per 
diagnoses in Serbia requires careful analysis.  
Study results show that 55.5% of all health 
insurance expenditures for reimbursed medicines in 
Serbia are allocated on antihypertensive drugs; that 
was significantly higher than in the other countries.12 
This fact underlines the significance of the cost 
analysis of hypertension pharmacotherapy and 
necessity of the strict control on antihypertensive 
medicines. Antihypertensive drugs accounted for 
more than half of the prescription drug 
expenditures, although only 18% of population had 
hypertension, according to the data. This could be 
commented as lack of precise epidemiological 
statistic for the hypertension burden and confirms 
the importance of the cost control measures.13 
Further analysis should be done in depth about the 
adequate control on the blood pressure and 
introduction of measures for patient’s education and 
compliance improvement, as well as study on the 
commitment of health care professionals. It could be 
kept in mind that the introduction of cost control 
measures could significantly increase the misuse of 
the medicines and therapy could failed but in any 
case clear evidences about the correspondence 
among the medicines usage and hypertension 
control are necessary for making any policy 
changes.  
The prevalence of the ACE inhibitors (37%) and 
calcium antagonist (22%) prescribing while the 
diuretics usage is only 10% and 3% as mono-
therapy and fix combination respectively could be 
explained with the existing marketing differences in 
terms of authorised for sale medicines as well as 
with the producers’ policy on the local markets.14,15 
High percentage of patients with complicated 
hypertension indicates late beginning of therapy, 
irregular general practitioner visits and low 
compliance.  
It is authors’ opinion that better cooperation 
between physicians and patients would lead to 
arterial hypertension morbidity and mortality 
reduction, reduction in expenditures for patient and 
society, which will finally affect patient’s quality of 
life. Further analysis is needed. 
 
CONCLUSIONS 
Our study confirms that hypertension and its 
complications therapy consumes a huge amount of 
financial resources.  
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In both countries under consideration the therapy is 
corresponding with the European treatment 
guidelines.  
We also could conclude that the international cost 
comparisons are possible but they depend on many 
external factors as the regulatory measures, 
prescribing habits and reimbursement policy and 
should be analysed within this framework. 
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